Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEUMOVAS pneumococcal vaccination intensification in ANCA-associated vasculitis on rituximab
2016-002888-33Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of pneumococcal 13-valent conjugate vaccine and Pneumo 23 in pneumococcal disease (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary immunogenicity endpoint at month 6. Started May 2017; status: active.
02
Drugs
pneumococcal 13-valent conjugate vaccinePneumo 23
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2016-002888-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002888-33.